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Within 17 months of the identification of SARS-CoV-2 in Wuhan, China, in response to the pandemic, 6 COVID-19 vaccines were recommended for use by the World 
Health Organization (WHO) as of 16 June 2021 (ref. 1). Vaccine 
efficacies (VE) ranging from 50% to 95% against symptomatic 
COVID-19 infections have been reported, using varying endpoint 
definitions2–7. Real-world evidence from vaccine-rollout programs 
has shown that COVID-19 vaccines are highly effective against 
severe disease, hospitalization, and death, and reduce both asymp-
tomatic infection and within household transmission8–13.
The global supply of COVID-19 vaccines remains limited despite 
intense production efforts. Authorization of new vaccines could help 
meet demand. As more countries implement vaccine programs, it will 
become increasingly difficult to conduct clinical efficacy studies of new 
vaccines. Understanding the relationship between immune responses 
to vaccines and protection against clinical outcomes is urgently needed 
to speed vaccine development. Knowledge of immune measures that 
are statistically associated with protection against disease (‘correlates 
of protection’) may allow new vaccines to be authorized for use on the 
basis of immunogenicity and safety data alone, when large efficacy tri-
als are not feasible. In addition, understanding the immune response 
allows for comparison of vaccines across cohorts of people who differ 
by age, race, ethnicity, or other factors.
Both binding and neutralizing antibodies are thought to be 
potential correlates of protection against COVID-19 and are cor-
related with each other3,14–16. Previous human challenge studies of 
seasonal coronaviruses reported high levels of baseline neutraliz-
ing antibodies in uninfected or asymptomatic people17. However, 
protection from infection with seasonal coronaviruses is not 
long-lasting17,18.
Early evidence from a fishery-vessel outbreak of SARS-CoV-2 
suggested that higher levels of pre-existing neutralizing antibod-
ies were potential correlates of protection18,19. A longitudinal cohort 
study of healthcare workers highlighted the association between base-
line anti-spike and anti-nucleocapsid immunoglobulin G (IgG) and 
decreased risk of SARS-CoV-2 infection in the following 6 months19,20.
Evidence that antibodies may play a role in mediating protec-
tion against overt disease has come from vaccination and chal-
lenge studies in animals. Both neutralizing antibody titers and 
Fc-dependent functional antibody responses correlate with pro-
tection induced by DNA and adenoviral vector vaccines in rhe-
sus macaques (Macaca mulatta)21,22. Additionally, higher doses of 
passively transferred monoclonal antibodies were more protective 
than were lower doses in golden hamsters (Mesocricetus auratus) 
and rhesus macaques challenged with the SARS-CoV-2 virus con-
taining D614 in its spike protein23.
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The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protec-
tion could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) 
vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. 
Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipi-
ents. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 
80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 
806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike 
and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutraliza-
tion titers (NF50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymp-
tomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and 
allow extrapolation of efficacy estimates to new COVID-19 vaccines.
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A meta-analysis modeling the relationship between VE reported 
from phase 3 vaccine clinical trials and neutralization titers in con-
valescent patients showed a significant association at the study level 
between VE and neutralizing antibody levels24. Nevertheless, no study 
to date has defined a correlate of protection against SARS-CoV-2 infec-
tion or disease that can be used by regulators and vaccine developers.
Table 1 | Baseline characteristics of correlates population, control population, and cases and noncases among correlates cohort
ChAdOx1 nCoV-19 
correlates population (n = 
4,372)
MenACWY control 
population (n = 4,194)
ChAdOx1 nCoV-19 correlates cohorta
Cases (n = 171) Noncases (n = 1,404)
Age group
 18–55 years 3,240 (74.1%) 3,229 (77%) 144 (84.2%) 1,005 (71.6%)
 56–69 years 542 (12.4%) 482 (11.5%) 10 (5.8%) 194 (13.8%)
 ≥70 years 590 (13.5%) 483 (11.5%) 17 (9.9%) 205 (14.6%)
Sex (Female) 2,533 (57.9%) 2,526 (60.2%) 102 (59.6%) 780 (55.6%)
Ethnicity
 White 4,036 (92.3%) 3,914 (93.3%) 160 (93.6%) 1,293 (92.1%)
 Asian 220 (5.0%) 184 (4.4%) 8 (4.7%) 71 (5.1%)
 Black 21 (0.5%) 15 (0.4%) 1 (0.6%) 10 (0.7%)
 Otherb 95 (2.2%) 81 (1.9%) 2 (1.2%) 30 (2.1%)
BMI (mean (s.d.)) 26.4 (5) 26.5 (5.2) 27 (5.2) 26.5 (5.1)
 BMI < 30 3,519 (80.5%) 3,347 (79.8%) 130 (76.0%) 1,124 (80.1%)
 BMI ≥ 30 852 (19.5%) 846 (20.2%) 41 (24.0%) 280 (19.9%)
Comorbidities 1,088 (24.9%) 1,032 (24.6%) 44 (25.7%) 360 (25.6%)
 Respiratory disease 547 (12.5%) 537 (12.8%) 20 (11.7%) 178 (12.7%)
 Cardiovascular disease 572 (13.1%) 514 (12.3%) 24 (14.0%) 192 (13.7%)
 Diabetes 99 (2.3%) 85 (2%) 3 (1.8%) 36 (2.6%)
Healthcare worker status
Nonhealthcare worker 1,652 (37.8%) 1,456 (34.7%) 65 (38.0%) 597 (42.5%)
 Healthcare worker facing no more than one 
patient with COVID-19 per day
1,904 (43.6%) 1,938 (46.2%) 74 (43.3%) 587 (41.8%)
 Healthcare worker facing at least one patient 
with COVID-19 per day
816 (18.7%) 800 (19.1%) 32 (18.7%) 220 (15.7%)
Baseline risk probabilitiesc
 Mean (s.d.) 0.0786 (0.0303) 0.0794 (0.0296) 0.0824 (0.0283) 0.0774 (0.0306)
Dosage schedule
 LD/LD 125 (2.9%) 69 (1.6%) 7 (4.1%) 114 (8.1%)
 LD/SD 1,420 (32.5%) 1,361 (32.5%) 46 (26.9%) 320 (22.8%)
 SD/SD 2,827 (64.7%) 2,764 (65.9%) 118 (69%) 970 (69.1%)
Prime-boost interval
 <6 weeks 1,078 (24.7%) 931 (22.2%) 28 (16.4%) 456 (32.5%)
 6–8 weeks 538 (12.3%) 478 (11.4%) 43 (25.1%) 197 (14%)
 9–11 weeks 1,158 (26.5%) 1,236 (29.5%) 42 (24.6%) 398 (28.3%)
 ≥12 weeks 1,598 (36.6%) 1,549 (36.9%) 58 (33.9%) 353 (25.1%)
Length of follow-up (days) from 7 days post 
PB28 until infection occurred or Feb 28 2021 
(median (IQR))
88 (64, 113) 85 (62, 108) 53 (29, 81) 105 (81, 135)
NAAT+ cases 174 333 171
 Symptomatic 55 (31.6%) 196 (58.9%) 54 (31.6%)
Asymptomatic 99 (56.9%) 112 (33.6%) 97 (56.7%)
Nonprimary symptomatic 20 (11.5%) 25 (7.5%) 20 (11.7%)
 BMI, body mass index; LD, low dose; SD, standard dose aThe correlates cohort is a subset of all eligible participants in the ChAdOx1 nCoV-19 correlates populations who have samples processed for at least 
one assay. bOptions included in ‘Other’ are as follows: ‘Mixed’, ‘Other – Free text’, or ‘prefers not to give’. cThe baseline risk exposure score summarizes predicted probability of having NAAT+ outcome from 
the risk model developed using the MenACWY Control Population.
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The ChAdOx1 nCoV-19 vaccine (AZD1222) is a chimpanzee 
adenoviral vector vaccine with full-length SARS-CoV-2 spike 
insert which was developed at the University of Oxford and is in 
widespread global use and produced by AstraZeneca and their 
manufacturing partners. Using data from the United Kingdom 
and Brazil, we previously estimated an overall VE of 66.7% (95% 
confidence interval (CI): 57.4 to 74.0) against symptomatic infec-
tion and 27.3% (95% CI: −17.2 to 54.9) against asymptomatic 
infection2,3. We previously showed that estimates of VE against 
symptomatic COVID-19 infection were higher in subgroups 
with higher pseudovirus neutralization antibody titers, or higher 
anti-spike IgG levels, in vaccine clinical trials of ChAdOx1 nCoV-
19 in adults using summarized data3. Here, we report the rela-
tionship between a continuous measure of the humoral immune 
responses to vaccination and protection afforded by this vaccine, 
which may facilitate further vaccine development. Specifically, we 
used individual data from the United Kingdom and identified the 
thresholds for four immune markers associated with protection 
against symptomatic infection. The WHO international standard 
units are reported for all assays, to allow comparisons across stud-
ies and platforms.
Results
Using the COV002 data from the United Kingdom, we assessed 
the correlation between immune markers at 28 days post the sec-
ond dose (post-boost + 28 days, PB28) of ChAdOx1 nCoV-19 
and symptomatic and asymptomatic infections. Participants were 
reminded weekly to contact their study site if they experienced any 
of the primary symptoms of COVID-19 (fever ≥ 37.8 °C; cough; 
shortness of breath; anosmia or ageusia) and were assessed in clinic 
with a nose and throat swab taken for nucleic acid amplification 
testing (NAAT). Additionally, participants were asked to complete a 
nose and throat swab at home each week, which was used to detect 
asymptomatic infections. Nucleic acid amplification test positive 
(NAAT+) participants who had symptoms other than the main five 
COVID-19 symptoms were categorized as nonprimary symptom-
atic and were not included in correlates analysis.
Table 1 summarizes baseline characteristics for the defined 
correlates population, control population, and correlates cohort 
by status (cases and noncases). Extended Data Fig. 1 summarizes 
the exclusions for each study group. Participants were followed for 
a median of 88 and 85 days, counting from 7 days after the PB28 
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Fig. 1 | Predicted absolute risk of primary symptomatic COVID-19 as a function of immune markers measured at PB28 by generalized additive 
regression. a–d, Predicted absolute risk of primary symptomatic COVID-19 as a function of anti-spike IgG measured at PB28 (52 cases, 1,155 noncases 
included in the analysis) (a), anti-RBD IgG measured at PB28 (52 cases, 1,155 noncases included in the analysis) (b), pseudovirus neutralization antibody 
titers at PB28 (47 cases, 828 noncases included in the analysis (c), and live-virus neutralization antibody titers PB28 (36 cases, 412 noncases included 
in the analysis) (d). Gray horizontal lines show the overall risk of primary symptomatic COVID-19 in the control group (MenACWY) and vaccine groups 
(ChAdOx1 nCoV-19). Blue dots show the absolute risk predicted from the model across the range of antibody values included in the analysis, adjusting for 
baseline exposure risk to SARS-CoV-2 infection. Green shaded areas show the CI around the predicted mean probability (green line).
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The follow-up time was censored at the earliest timing of infec-
tion, withdrawal, or unblinding, or the cut-off date 28 February 
2021. Among 4,372 participants in the correlates popula-
tion, there were a total of 174 breakthrough NAAT+ cases of 
SARS-CoV-2 infection. Data were available for at least one of four 
assay readouts (anti-spike IgG, anti-receptor binding domain 
(RBD) IgG, pseudovirus neutralization assay, and live-virus neu-
tralization) for 171 out of 174 (98.3%) cases and 1,404 out of 
4,195 (33.5%) noncases. Data were available for anti-spike and 
anti-RBD IgG from 1,318 PB28 samples (163 cases and 1,155 non-
cases, Supplementary Table 2). A smaller set of data was avail-
able for analysis for pseudovirus neutralization titers (149 cases, 
828 noncases) and for live-virus neutralization (110 cases and 
412 noncases) (Supplementary Table 2). People in the case group 
were younger, with 84.2% being aged 18–55 years, compared with 
71.6% of the noncase group, and were more likely to be healthcare 
workers (62.0% were healthcare workers compared with 57.5% 
of the noncase group, Table 1). In our baseline exposure model 
developed among the MenACWY control group, younger age 
and being a healthcare worker facing more than one patient with 
COVID-19 per day were associated with a higher risk of being 
NAAT+. Other variables were not significant (see model output 
in Supplementary Table 3). The distribution of baseline risk was 
similar for cases and noncases (Table 1).
Antibody levels at PB28 in cases and noncases across four 
immune markers are shown in Extended Data Fig. 2. Anti-spike 
IgG and anti-RBD IgG were highly correlated with each other 
(Pearson correlation coefficient r = 0.926), while the correlation 
between pseudovirus neutralization titer and normalized live-virus 
neutralization titer (NF50) was moderate (r = 0.572). Anti-spike IgG 
values were also correlated with pseudovirus neutralization titers 
(r = 0.657) and normalized live-virus neutralization titers (NF50) 
(r = 0.600) (Extended Data Fig. 3). Non-normalized live-virus neu-
tralization titers (ND50) were less highly correlated with anti-spike 
IgG (r = 0.411) and pseudovirus neutralization titers (r = 0.305).
The risk of symptomatic COVID-19 decreased with increas-
ing levels of anti-spike IgG (P = 0.003), anti-RBD IgG (P = 0.018), 
pseudovirus neutralization titer (P = 0.005), and live-virus neu-
tralization titer (P < 0.001) (Figs. 1 and 2 and Table 2). In contrast, 
there were no significant associations between any of the assays 
and protection against asymptomatic infection including for sen-
sitivity analysis restricting to high viral load (all P > 0.05, Fig. 3, 
Extended Data Figs. 4, and 5, and Supplementary Table 4). When 
primary symptomatic COVID-19 cases were classified according 
to the presence of shortness of breath, we observed a similar trend, 
with increasing immune marker levels associated with lower risk of 
infection (all P < 0.05, Supplementary Table 4 and Extended Data 
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Fig. 2 | Relative risk of primary symptomatic COVID-19 among vaccine recipients compared with MenACWY control arm participants as a function of 
immune markers measured at PB28. a, Anti-spike IgG measured at PB28 (52 cases, 1,155 noncases included in the analysis). b, Anti-RBD IgG measured 
at PB28 (52 cases, 1,155 noncases included in the analysis). c, Pseudovirus neutralization antibody titers at PB28 (47 cases, 828 noncases included in the 
analysis). d, Live-virus neutralization antibody titers at PB28 (36 cases, 412 noncases included in the analysis). Blue shaded areas represent the immune 
marker density distribution. Green lines show the relative risk of infection among vaccine recipients compared with that of the MenACWY control arm 
participants, derived by dividing the output curve from Fig. 1 by the overall risk of infection in the MenACWY control group. The green lines are the 
median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are 95% bootstrapped CIs for the relative risk. The arrows point to 
the immune marker values at 0.20 and 0.50 relative risk, that is 80% and 50% VE for illustrative purpose. The full range of VE estimates from 50 to 
90% are shown in Table 2.
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Supplementary Table 4 and Extended Data Fig. 7). Higher pseu-
dovirus and live-virus neutralization titers were associated with 
lower risk of infection for those who had three or more COVID-19 
symptoms (Supplementary Table 4 and Extended Data Fig. 8). 
The number of cases and noncases included for correlates analy-
sis by each immune marker and outcome has been summarized in 
Table 2 and Supplementary Table 4.
The antibody level associated with 80% VE against primary 
symptomatic COVID-19 was 40,923 (95% CI: 16,748, 125,017) arbi-
trary units (AU)/ml for anti-spike IgG, equivalent to 264 BAU/ml 
(95% CI: 108, 806) using the WHO international standard (NIBSC 
code 20/136). For anti-RBD IgG, 80% efficacy was achieved with 
median antibody level of 506 (95% CI: 135, not computed (NC)) 
BAU/ml (Figs. 2 and 4 and Table 2).
For pseudovirus and live-virus neutralizing antibody titers, val-
ues of 26 (95% CI: NC, NC) IU/ml and 247 (95% CI: 101, NC) nor-
malized neutralization titers (NF50), respectively, were associated 
with 80% VE against symptomatic infection (Table 2). No values 
from these assays were associated with protection against asymp-
tomatic infection (Supplementary Table 4)
For all assays, when the analysis was restricted to symptomatic 
cases with shortness of breath, 80% VE was achieved at lower levels 
of immune markers than for symptomatic cases in general. Higher 
baseline exposure risk of SARS-CoV-2 infections predict higher 
probability of all outcomes (all P < 0.05, Table 2 and Supplementary 
Table 4), except for asymptomatic infections (P > 0.05) in general-
ized additive models.
Discussion
Here, we report an analysis of potential correlates of protection 
using data from 171 cases of SARS-CoV-2 infection and 1,404 
noncases, showing that higher anti-spike IgG, anti-RBD IgG, and 
neutralizing antibody titers are all associated with lower risk of 
symptomatic disease. We used immune responses in a phase 2/3 
clinical trial to derive a model to predict absolute risk of infection, 
with appropriate adjustment for bias, assigning estimates for each 
level of antibody in the dataset. The relative risk of infection was 
then derived by reference to risk of infection in the control group. 
This is a robust approach to derive population estimates and was 
adapted from recently described methods25,26.
We previously published overall aggregate-level summaries of 
antibody levels in participants with different prime-boost inter-
vals. Vaccination prime-boost intervals were associated with vary-
ing levels of VE, and there are some intriguing similarities between 
the aggregate-level data with the estimate provided from analysis 
of individual participant level data in this report. The estimated 
anti-spike IgG level of 40,923 AU/ml and the pseudovirus neutral-
izing antibody titer of 185 associated with 80% VE in our models 
were similar to the geometric mean titers of 48,961 AU/ml and 
237.0, respectively, previously reported in the subgroup of partici-
pants vaccinated with ChAdOx1 nCoV-19 with a dose interval of 
at least 12 weeks between their first and second dose—a regimen 
that provided 80.0% (95% CI 65.2 to 88.5) VE in the pooled analysis 
of clinical trial data from the United Kingdom, Brazil, and South 
Africa3. The aggregate-level results previously published included 
all eligible participants in the assessment of VE, but only those with 
available antibody data were included in the summaries of immu-
nogenicity, meaning that direct comparisons of efficacy with immu-
nogenicity were not in the same populations. Our current approach 
analyzes the relationship between infections and antibody levels at 
the individual level in a single set of participants, with appropriate 
adjustment for confounding, providing robust outputs. In addition, 
the current work provides outputs in WHO standard units, which 
are necessary for comparisons with data from other laboratories 
with different assays.
In a preprint by Gilbert et al., correlates of protection derived 
from the Moderna phase 3 efficacy trial are reported using simi-
lar methodology27. Although overall binding and pseudovirus 
neutralizing antibody titers after vaccination were higher in that 
study than those measured after the ChAdOx1 nCoV-19 vaccine, 
the correlates of protection findings appear similar to those we 
report here.
Table 2 | Outputs from generalized additive models, with immune marker values associated with 50%, 60%, 70%, 80%, and 90% 
VE against symptomatic infection
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(95% CI)
Anti-spike IgG
























BAU/ml 17 (NC, 109) 50 (NC, 232) 165  
(NC, 452)
506 (135, NC) 2360  
(723, NC)
Normalized live-virus neutralization assay
NF50 <0.001 <0.001 36 412 68 (NC, 129) 91 (NC, 175) 135 (48, 267) 247 (101, NC) 938 (294, NC)
Pseudovirus neutralization assay
ID50 0.005 <0.001 47 828 NC 22 (NC, 76) 57 (NC, 183) 185 (NC, NC) 982 (303, NC)
IU/ml NC 3 (NC, 11) 8 (NC, 26) 26 (NC, NC) 140 (43, NC)
ID50: neutralization dilution for 50% virus inhibition; NC: not computed; AU/ml: arbitrary units per mL; BAU/ml: binding antibody units per ml (WHO international standard 20/136), IU/ml: international 
units per ml (WHO international standard 20/136). Where CIs were outside the range of values of the assay the limits are reported as NC. VE estimates and CIs are those shown in Fig. 4, at every 10% 
increment in the y axis. The two-sided P value for each immune marker (column 2) is from the generalized additive models in Fig. 1, showing the strength of the relationship between the antibody value and 
infection. The P values were not adjusted for multiple comparisons.
NATuRE MEDICINE | VOL 27 | NOVEMBER 2021 | 2032–2040 | www.nature.com/naturemedicine2036
ArticlesNature MediciNe
No serological measurements in our data were shown to correlate 
with protection against asymptomatic infection or against symp-
tomatic illness with only mild upper respiratory symptoms. This is 
consistent with our interim analysis that VE against asymptomatic 
infection was 27.3% (95% CI: −17.2 to 54.9) and was not signifi-
cant at the 5% level2. These results are consistent with the real-world 
observation that infection remains possible in fully vaccinated indi-
viduals, despite high effectiveness against severe disease.
The antibody correlates presented in this report relate to protec-
tion against mild disease, defined as a NAAT+ test with at least one 
symptom present. Weekly self-swabbing in the trial enabled detec-
tion of many mild cases. At these antibody titers, efficacy against 
more severe endpoints, used in other trials, would be higher than 
the estimates in this analysis. Notably, this has been confirmed in 
the analysis of real-world effectiveness, in which the milder cases 
are not detected, after two doses of the vaccines in older adults 
in England, where VE was 90% for Pfizer and 89% for ChAdOx1 
nCoV-19 against symptomatic disease using the same case defini-
tion for both vaccines11, while lower efficacy estimates were mea-
sured in our previously reported efficacy analysis with a milder 
disease endpoint2.
The correlates of vaccine efficacy reported here could be used 
to extrapolate efficacy to immunogenicity data for novel vaccines 
where clinical efficacy results are unavailable. A trial of a new vac-
cine that works through similar immune mechanisms and which 
produces antibody responses that are above the correlate values 
reported here in at least 50% of participants (that is, it has a simi-
lar or higher median), might be expected to have similar efficacy 
against the clinical endpoints used in our UK trial, and higher 
efficacy against more severe endpoints. We provide correlates for 
vaccine efficacy estimates ranging from 50% to 90% to allow flex-
ibility in the way these estimates are utilized by the regulators and 
policy-makers.
It has previously been shown that protection against lower respi-
ratory tract infection (LRTI) may be easier to achieve than against 
upper respiratory tract infection (URTI), as challenge studies in 
rhesus macaques have shown stronger correlation between neutral-
izing titers and the level of subgenomic messenger RNA in bron-
choalveolar lavage samples than in nasal swab samples28.
Similarly, ChAdOx1 nCoV-19-vaccinated hamsters, with low 
neutralizing titers against B.1.351, were fully protected against LRTI 
following challenge with B.1.351, despite no evidence of protec-
tion against shedding of virus from the upper airway29. Protection 
against upper respiratory tract or asymptomatic infections may be 
more closely associated with the presence of secretory IgA on the 
mucosal surface which was not measured in this study30.
These observations indicate that the reduced neutralizing capac-
ity against B.1.351 and other variants of concern, might drive 
reduced protection against initial infection, and perhaps transmis-
sion, but protection against severe disease is maintained. Clinical 
trials of SARS-CoV-2 vaccines have consistently shown higher effi-
cacy against more severe forms of disease, such as those causing 
hospitalization or death, than against mild infections2–5,15,31. We are 
unable to assess correlates of protection against severe disease or 
hospitalization as there were no vaccinated participants hospitalized 
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Fig. 3 | Relative risk of asymptomatic SARS-CoV-2 infection among vaccine recipients compared with the MenACWY control arm participants as a 
function of immune markers measured at PB28. a, Anti-spike IgG measured at PB28 (91 cases, 1,155 noncases included in the analysis). b, Anti-RBD 
IgG measured at PB28 (91 cases, 1,155 noncases included in the analysis). c, Pseudovirus neutralization antibody titers at PB28 (86 cases, 828 noncases 
included in the analysis). d, Live-virus neutralization antibody titers at PB28 (62 cases, 412 noncases included in the analysis). Blue shaded areas represent 
the immune marker density distribution. Green lines show the relative risk of infection among vaccine recipients compared with the MenACWY control 
arm participants. The green lines are the median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are bootstrapped 95% CIs.
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Although live-virus and pseudovirus neutralization assays were 
modestly correlated with each other, the live-virus assay was more 
closely associated with protection against symptomatic COVID-19 
than was the pseudovirus assay. This may reflect the sensitivity and 
dynamic range of the assays.
Protection against symptomatic COVID-19 is not absolute with 
any vaccine, and the results presented here show that there is no 
single threshold value for any of the assays investigated that was 
indicative of sterilizing immunity in our data. Instead, the probabil-
ity of infection decreases on average with higher immune responses, 
but substantial variation exists between individuals. This is similar 
to studies of respiratory syncytial virus, in which risk of infection 
decreased with higher antibody levels, although infections were still 
observed at high antibody levels, suggesting that a definitive indi-
vidual threshold of protection does not exist32. We provide antibody 
estimates that correspond with 50% to 90% VE; however, the wide 
CIs around these estimates should be noted.
These estimates represent the antibody level observed 28 days 
after a second dose of vaccine that provide protection during the 
subsequent 4- to 6-month period among UK COV002 efficacy and 
immunogenicity cohorts. This is different from the antibody level 
that would protect an individual at the time of exposure to the virus. 
Further work is needed to determine the durability of antibody and 
long-term protection after vaccination.
High levels of protection were noted after vaccination with one 
dose of a lipid nanoparticle RNA vaccine, despite modest levels of 
neutralizing antibody, strongly supporting the concept that other 
mechanisms are at play as co-correlates of protection5,33. We have 
previously shown that a wide range of Fc-mediated antibody func-
tions are induced by vaccination, and it is possible that these func-
tions may be important in the absence of neutralizing antibody34. 
Furthermore, strong T cell responses induced by ChAdOx1 nCoV-
19 may contribute to protection14,16 and have been associated with 
recovery from COVID-19 disease35–37. The relationship between 
antibody and T cell responses may differ depending on the type of 
vaccine used, and care should be taken when interpreting data from 
clinical testing of different vaccine technologies.
There are some limitations to our analysis. These analyses are 
based on cases of COVID-19 detected in a mainly white popula-
tion in the United Kingdom, which were mostly due to B.1.177 and 
B.1.1.7 variants. In settings in which these are not the dominant 
variants causing disease, or where neutralization assays use differ-
ent strains of the virus, the modeled relationships between immune 
markers and disease outcomes shown here may not apply. In addi-
tion, we have conducted a large number of analyses, and therefore 
some caution should be taken when drawing conclusions on the 
basis of single P values alone as these are presented unadjusted 
for multiple comparisons. Furthermore, these analyses have been 
conducted on samples taken after two doses of ChAdOx1 nCoV-
19 and might not apply to protection afforded by a single dose of 
the same vaccine or other COVID-19 vaccines. Correlates may also 
vary according to age profile, but this was not explored in our study 
due to the small number of older adults recruited. The potential role 
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Fig. 4 | VE against primary symptomatic COVID-19 as a function of immune markers measured at PB28. a, Anti-spike IgG measured at PB28 (52 
cases, 1,155 noncases included in the analysis). b, Anti-RBD IgG measured at PB28 (52 cases, 1,155 noncases included in the analysis). c, Pseudovirus 
neutralization antibody titers at PB28 (47 cases, 828 noncases included in the analysis). d, Live-virus neutralization antibody titers at PB28 (36 cases, 412 
noncases included in the analysis). Blue shaded areas represent the immune marker density distribution. Green lines show the VE, and green dotted lines 
are 95% bootstrapped confidence intervals for VE. VE is computed as 1 minus the relative risks shown in Fig. 2. These results are also shown in Table 2 at 
10% increments on the y axis.
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has not been evaluated in this study. It is not possible to determine 
in this study if our results represent mechanistic or nonmechanis-
tic correlates of protection, as many immune responses are highly 
correlated.
Correlates of protection can be used to bridge to new popula-
tions and new vaccines using validated assays. These data can be 
used to extrapolate efficacy estimates for new vaccines that use 
similar immune mechanisms and where efficacy data is unavailable.
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Methods
Study description. The data included in this analysis comes from participants 
enrolled in COV002 (registration NCT04400838), a phase 2/3 randomized 
single-blind vaccine efficacy trial conducted across 19 sites in the United Kingdom. 
A full description of the trial including immunogenicity, efficacy, and safety data, 
and the protocol has been previously published2,3,14,15,38.
This study was approved in the United Kingdom by the Medicines and 
Healthcare products Regulatory Agency (MHRA), reference 21584/0428/001 
0001, and the South-Central Berkshire Research Ethics Committee, reference 20/
SC/0179. All participants provided informed consent.
Briefly, participants in the study were randomized to receive ChAdOx1 
nCoV-19 or a MenACWY control vaccine. The randomization ratio (ChAdOx1 
nCoV-19:MenACWY) differed by study cohort, and was either 1:1, 5:1, or 3:1. (see 
CONSORT diagram, Extended Data Fig. 1). Open label groups are not included in 
this report.
Study endpoints and outcomes. Participants were reminded weekly to contact 
their study site if they experienced any of the primary symptoms of COVID-19 
(fever ≥ 37.8 °C; cough; shortness of breath; anosmia or ageusia) and were assessed 
in clinic, with a nose and throat swab taken for NAAT. In addition, participants 
were asked to complete a nose and throat swab at home each week.
The outcomes for this analysis were (1) primary symptomatic COVID-19, that 
is a NAAT+ swab with at least one qualifying symptom, and (2) asymptomatic 
infections identified from weekly self-administered swabs, defined as a NAAT+ 
swab with no symptom reported. Sensitivity analysis of asymptomatic infections 
removed potential false-positive cases by restricting to those with higher viral 
load (cycle threshold (CT) value < 30). NAAT+ participants who had symptoms 
other than the main five COVID-19 symptoms were categorized as nonprimary 
symptomatic and were not included in correlates analysis.
Primary symptomatic COVID-19 outcomes were further classified according 
to whether a symptomatic participant reported shortness of breath or not, and 
whether three or more COVID-19 symptoms among five were present, indicators 
of more severe disease.
All endpoints were evaluated by a blinded independent clinical review committee.
Immune markers and time points. A proportion of serum samples from vaccine 
recipients at PB28 were tested on 3 different assays with 4 assay readouts. All 
NAAT+ cases were tested if sample volume allowed, and a proportion of noncases 
were tested. Samples were tested blinded to case status. The data from noncases 
were obtained first, and consisted mainly of the samples processed for the initial 
application for emergency use which needed 15% of samples included in the 
efficacy cohort to be processed on validated assays. Subsequent to this NAAT+ 
cases were sent for testing as they occurred, if not already including the 15%. 
We assume the mechanism of missingness for samples that were not tested to 
be missing at random39. To account for the missing data, factors associated with 
sample availability were controlled as weights in the analysis (see ‘Correlates of risk’ 
and ‘Inverse probability weighting’ below).
Anti-SARS-CoV-2 Spike and RBD IgG were measured by a multiplex 
immunoassay on the MSD platform at PPD Laboratories. The assay sequences 
were based on the ancestral sequences from Wuhan, China. Antigen information 
and sequence information are provided in Supplementary Table 1. Assay validation 
included precision and ruggedness, dilutional linearity, selectivity, and relative 
accuracy for each SARS-CoV-2 antigens. Post-validation studies for stability and 
for conversion to the WHO standard, as well as the establishment of a cut-point, 
were performed. The lower limit of quantifications (LLOQs) for anti-spike and 
anti-RBD are 33 and 204 AU/ml, respectively.
Antibody neutralization was measured with a lentivirus-based pseudovirus 
particle expressing the D614 SARS-CoV-2 spike protein. The pseudovirus 
neutralizing antibody assay was validated at Monogram Biosciences. Validation 
included accuracy, repeatability, intermediate precision, linearity, specificity/
selectivity, sensitivity, and stability utilizing pooled sera from high-titer, 
intermediate-titer, and low-titer pooled convalescent SARS-CoV-2 sera, as well 
as historical negative samples collected in the year 2017 (prior to SARS-CoV-2 
circulation). The LLOQ for pseudovirus neutralizing antibody is 40 (ID50).
Antibody neutralization was also measured by a live microneutralization 
assay using the Victoria/01/2020 strain of the virus (Public Health England). 
Qualification of the assay included assessment of specificity, parallelism, 
dilutional linearity, repeatability, intermediate precision, and assessment of the 
assay range. A formal validation has since been completed (after the testing of 
clinical study samples in this manuscript). Normalized values (NF50) were used 
for the main analyses, as the normalization process removes the plate-to-plate 
variability and normalized values are more highly correlated with binding 
antibody and pseudovirus neutralization assays. However, normalized values 
cannot be converted into WHO standard units. A sensitivity analysis is provided 
in Supplementary Table 4 using non-normalized values (ND50), which are also 
presented as IU/ml using the WHO standard, but are less highly correlated with 
other assays. The LLOQ of the assay is 58 (ND50) and 8.6 (NF50).
Due to the limitations of laboratory capacity, fewer samples were tested for 
virus neutralization than were tested using the quicker multiplex assay.
Imputation on censored immune marker data in main analysis. Immune marker 
values were log10-transformed prior to analysis. Values that were censored at 
the lower limit of quantification (LLOQ) were imputed with the value LLOQ/2. 
Approximately 10% of the pseudovirus neutralization titer was censored at the 
LLOQ, and sensitivity analyses were conducted by imputing these values using a 
Gibbs sampler.
Conversion to WHO International Standard (20/136). Each assay was analyzed 
in its original scale, and results were then converted to the WHO international 
standard units using the conversion factors supplied by each laboratory. WHO 
standard units are BAU/ml for anti-spike and anti-RBD IgG, and IU/ml for 
neutralization titers40. For PPD conversion, factors are supplied with CIs. These are 
not able to be applied to the converted data, as it is a one-to-one conversion. For 
the Monogram assay, multiple forms of the conversion factor were supplied, and all 
three were implemented.
Conversion factors were as follows:
PPD: Conversion from AU/ml to BAU/ml
•	 Anti-spike IgG 0.00645, 95% CI (0.00594, 0.00701)
•	 Anti-RBD IgG 0.00798, 95% CI (0.00735, 0.00866)
Monogram pseudovirus neutralization assay (D614) conversion from ND50  
to IU/ml
•	 0.1428 (mean)
•	 0.1458 (geometric mean)
•	 0.1534 (median)
PHE live-virus neutralization assay conversion from ID50 to IU/ml
•	 0.2461 (1/4.064)
Study design and analysis populations. We first defined the correlates population 
by restricting it to participants who met the eligibility criteria and received 
ChAdOx1 nCoV-19: participants were eligible for inclusion if they were baseline 
seronegative to the SARS-CoV-2 N protein at first vaccination, had their PB28 
visit within a 14- to 42-day window after the second dose, and were followed 
up to at least 7 days after PB28, with no prior evidence of infection. Participants 
were excluded from analysis if infection occurred before PB28. Participants who 
received two doses were included in the analysis, either standard dose followed by 
standard dose (SD/SD), or low dose followed by low or standard dose (LD/SD or 
LD/LD). Nine participants who received mixed schedules (one dose of ChAdOx1 
nCoV-19 and one dose of MenACWY control) in error were excluded from 
analysis (Extended Data Fig. 1). The same eligibility criteria were applied to define 
a control population of MenACWY recipients.
Among the ChAdOx1 nCoV-19 correlates population, those who had 
biomarker data available comprised the correlates cohort. Participants who tested 
NAAT+ more than 7 days after PB28 were defined as cases, while those who 
did not have a positive test were defined as noncases. The 7-day window was 
implemented to exclude cases in which exposure is likely to have occurred before a 
blood sample was taken.
Statistical Analysis. Baseline exposure risk to SARS-CoV-2 infections. To control 
for potential confounding due to variation in exposure risk among participants 
with available immune marker data, a logistic regression risk model was developed 
among the control population of MenACWY recipients. Baseline factors associated 
with exposure risk were used to model the probability of being NAAT+ in this 
population. Baseline variables for the risk model included age in years, ethnicity 
(white and nonwhite), BMI (<30 kg/m2, ≥30 kg/m2), comorbidities (having 
any of: respiratory disease; cardiovascular disease; or diabetes), and healthcare 
worker status (nonhealthcare worker, healthcare worker exposed to no more 
than one patient with COVID-19 on an average day; healthcare worker exposed 
to one or more patients with COVID-19 on an average day). Output is shown 
in Supplementary Table 3. The linear predictor from the risk model developed 
using the MenACWY control population was used to predict the baseline risk of 
exposure in the ChAdOx1 nCoV-19 correlates cohort.
Correlates or risk. The correlates of risk (CoR) analysis was conducted within 
the correlates cohort. log-transformed immune marker values were analyzed 
using generalized additive models (GAM) for binary data, with a cubic spline 
smooth applied to immune marker values to allow a nonlinear effect. The 
logit-transformed predicted baseline exposure risk was included as a linear 
covariate in the GAM model. A P value < 0.05 from the approximate significance 
test from the smooth GAM was used to determine if an immune marker was 
associated with protection. There was no adjustment for multiple comparison. 
Separate models were fitted for each immune marker controlling for baseline 
exposure risk, and weighted by inverse probability weights as described below.
Inverse probability weighting. Immune marker data were not available for everyone 
in the correlates population, and cases are over-represented in the immune marker 
datasets as these were preferentially processed over noncases. Unadjusted estimates 
of absolute risk of infection will therefore be inflated and result in bias to correlates 
estimates. We used a logistic regression model to predict the probability that a 
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participant will have immune marker data available to the analysis. The outcome 
variables were each immune marker, and predictors were age group (18–55 years, 
56–69 years, 70 years or above), whether the participant is a case or noncase, the 
type of case (primary symptomatic, nonprimary symptomatic, asymptomatic), 
prime-boost interval, and dosage (LD/LD, LD/SD, SD/SD). The inverse probability 
from this model was used to weight the correlates of risk models for each immune 
marker to remove this source of bias (Supplementary Table 3).
Correlates of vaccine efficacy. For each outcome, to derive the relative risk (RR) and 
correlates of vaccine efficacy, an estimate of the absolute averaged predicted risk 
from the CoR model was computed. The averaged absolute risk was then compared 
to the overall risk among MenACWY Correlates Population, which was itself 
weighted by the randomization ratio for study groups not randomized 1:1.
VE was defined as 100% × (1 – RR). Mean estimate of VE at each level  
of antibody in the dataset, as well as 95% CIs were calculated from 10,000 
bootstrap samples.
Further analysis details are provided with the original trial statistical  
analysis plan (SAP) and the separate SAP developed for immune correlates 
analyses. The immune correlates SAP leant heavily on the methods proposed in 
the publicly available SAP by the Coronavirus Prevention Network (CoVPN) 
Biostatistics Team26.
Bootstrap. We resampled from all participants enrolled in the study. For each 
bootstrap sample, we calculated the inverse probability weights to account for 
sampling bias. We then estimated the CoR by GAM, adjusting for the baseline risk 
exposure and weighting by inverse probability weights. We compared the predicted 
absolute risk from the GAM across the full range of antibody values, with the 
resampled MenACWY control population weighted overall risk. Ten thousand 
bootstrap samples were used for each immune marker and outcome. The overall 
estimates for CoR and correlates of vaccine efficacy were given by the median value 
in the bootstrap; 95% CIs were calculated using the bootstrap percentile method, 
that is, the 2.5% and 97.5% quantiles from the bootstrap.
Correlates and their CIs were not computed for assays in which the relationship 
between antibody and outcome was nonsignificant. Where CIs were outside the 
range of values of the assay, these are reported as NC.
Sensitivity analyses. Viral load. To account for potential of misclassification in 
asymptomatic infections, a sensitivity analysis was conducted excluding cases with 
lower viral loads (defined as those for whom all returned PCR positive tests had a 
CT value ≥ 30), as these are potential false positives.
Imputation of censored antibody values. Approximately 10% of the pseudovirus 
neutralization antibody titers were below the LLOQ. We performed a sensitivity 
analysis to account for the potential bias caused by imputing LLOQ / 2. Studies 
have shown that imputing LLOQ / 2 can lead to bias and CIs with poor coverage 
when a substantial proportion of the data are censored41–43. When a bootstrap is 
required for missing data, Brand et al. found single imputation embedded inside 
a bootstrap showed better statistical properties than other methods43. We used 
an iterative Gibbs sampler proposed by Chen et al. to impute the censored log 
pseudovirus neutralization antibody values42.
Not all participants with results from the pseudovirus neutralization titer also 
have results from the anti-spike, anti-RBD, and live neutralizing antibody titers. 
For each bootstrap sample, we iteratively predicted the missing and censored 
values for each antibody titers in a Gibbs sampler, constraining the predictions 
for the censored values to be less than or equal to the LLOQ. The antibody titers 
were iteratively predicted by a sequence of Bayesian linear regressions. For each 
regression, the independent variables were the current prediction for all other 
titers, the baseline risk score and all variables used in the inverse probability 
weighting model.
Let Zj, j = 1, 2, 3, 4 be the vector of the jth antibody titers values. Let σ2j  and 
βj be the variance and vector of regression parameters for the jth linear regression 










Then the Gibbs sampler proposed by Chen et al. is as follows:42
Initialize the missing and censored values Z(0)j  for each Zj, j = 1, 2, 3, 4.
For i = 1, …, N
For j = 1, 2, 3, 4
Update σ2j  and βj from the posterior distribution given the current predictors 
for all other antibody values Z(i)k , k < j; Z
(i−1)
k , k > j and the fixed covariates.
Update Z(i)j  from the posterior predictive distribution given σ
2
j  and βj and the 
current values of the predictor variables.
We imputed a single value for each of the censored log pseudovirus 
neutralization antibody values from the n = 100th iteration of the Gibbs sampler. 
Note participants with missing log pseudovirus neutralization antibody titer values 
were excluded from the sensitivity analysis. The sensitivity analysis was then run 
on the imputed dataset for the bootstrap sample.
We initialized the Gibbs sampler by predicting the missing and censored values 
from a sequence of linear regressions on the nonmissing data. This sequence was 
developed with the data structure in mind, aiming to initialize the chain as close to 
the posterior mode as possible.
We ran multiple chains on bootstrap samples and tested for convergence by 
inspecting trace plots of the censored log pseudovirus neutralization titers. From 
these plots, we determined the 100th iteration to be approximately converged.
Data cut-off. The data cut-off date for inclusion in this analysis was 28 February 
2021. Cases occurring after this date are not included in the analysis.
Software. Data analysis was done using R version 3.6.1 (ref. 45). The GAM was 
coded using the mgcv package46. Three knots were used for each GAM, and the 
smoothing parameter was estimated by generalized crossvalidation.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Anonymized participant data will be made available when the trials are complete, 
upon requests directed to the corresponding author. Proposals will be reviewed and 
approved by the sponsor, investigator, and collaborators on the basis of scientific 
merit. After approval of a proposal, data can be shared through a secure online 
platform after signing a data access agreement. All data will be made available for a 
minimum of 5 years from the end of the trial.
Code availability
The R code for the main correlates estimates is available in Supplementary File 
(item 5, page 8).
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Single blind immunogenicity and efficacy cohorts receiving ChAdOx1 n-CoV 19
Extended Data Fig. 1 | Participant flow chart showing inclusion in correlates models. Eligible participants comprised the Correlates Population and those 
with samples processed comprised the Correlates Cohort.







































































Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | Immune markers measured at day 28 post-second dose, in primary symptomatic, asymptomatic, non-primary cases, NAAT 
positive cases and NAAT negative non-cases. a: N = 1155 NAAT negative, 52 primary, 91 asymptomatic and 20 non-primary, b: N = 163 NAAT positive 
participants’ anti-spike IgG measured at 28 days post boost; c: N = 1155 negative, 52 primary, 91 asymptomatic and 20 non-primary, d: N = 163 NAAT 
positive participants’ anti-RBD IgG measured at 28 days post boost; e: N = 828 NAAT negative, 47 primary, 86 asymptomatic and 16 non-primary, f: N = 
149 NAAT positive participants’ pseudovirus neutralisation titre measured at 28 days post boost; g: N = 412 negative, 36 primary, 62 asymptomatic and 12 
non-primary, h: N = 110 NAAT positive participants’ live neutralisation titre measured at 28 days post boost. a–h: minima: smallest value; maxima: largest 
value; centre: median value; bounds of box: 25% and 75% quartile value; upper/lower whisker extends from the hinge to the largest/smallest value no 
further than 1.5 * inter-quartile range from the hinge. IgG: Immunoglobulin G; RBD: receptor binding domain. Primary symptomatic cases: NAAT+ with at 
least one COVID symptom (cough, fever, shortness of breath, anosmia, aguesia). Asymptomatic cases: NAAT+ on weekly self-swab with no symptoms 
recorded. Non-primary cases: NAAT+ with only non-primary COVID symptoms (for example nausea, diarrhoea). P-value estimated by one-way ANOVA 
test comparing between primary, asymptomatic, non-primary cases and NAAT negative non-cases and by two sample t-test comparing between NAAT 
positive cases and NAAT negative non-cases (two-sided).








































































































Extended Data Fig. 3 | Correlations between a, Anti-SARS-CoV-2 spike and RBD IgG. b, Anti-SARS-CoV-2 Spike IgG and pseudovirus neutralisation 
titre. c, Anti-SARS-CoV-2 Spike IgG and live virus neutralisation titre. d, pseudovirus neutralisation titres and live virus neutralisation titres. 95% 
confidence ellipses assuming a t-distribution are shown for each outcome (primary symptomatic cases, asymptomatic cases and negative controls). 
Pearson correlation coefficients shown as r values using all available data. Primary symptomatic cases: NAAT+ with at least one COVID symptom (cough, 
fever, shortness of breath, anosmia, aguesia). Asymptomatic cases: NAAT+ on weekly self-swab with no symptoms recorded.
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Extended Data Fig. 4 | Predicted absolute risk of asymptomatic SARS-CoV-2 infection as a function of immune markers measured 28 days post second 
dose. Predicted absolute risk of asymptomatic infection as a function of: a: Anti-spike IgG measured at 28 days post boost (91 cases, 1155 non-cases 
included in the analysis). b: Anti-RBD IgG measured at 28 days post boost (91 cases, 1155 non-cases included in the analysis). c: Pseudovirus neutralisation 
antibody titres 28 days post boost (86 cases, 828 non-cases included in the analysis). d: Live-virus neutralisation antibody titres 28 days post boost 
(62 cases, 412 non-cases included in the analysis). Grey horizontal lines show the overall risk of primary symptomatic COVID-19 in the control group 
(MenACWY) and vaccine groups (ChAdOx1 nCoV-19). Blue dots show the absolute risk predicted from the model across the range of antibody values 
included in the analysis, adjusting for baseline exposure risk to SARS-CoV-2 infection. Green shaded areas show the confidence interval around the 
predicted mean probability (green line).
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Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Sensitivity analysis showing absolute and relative risk of asymptomatic SARS-CoV-2 infection as a function of immune markers 
measured at 28 days post second dose excluding cases with low viral load (Ct ≥ 30). a, c, e, g: Grey horizontal lines show the overall risk of primary 
symptomatic COVID-19 in the control group (MenACWY) and vaccine groups (ChAdOx1 nCoV-19). Blue dots show the absolute risk predicted from the 
model across the range of antibody values included in the analysis, adjusting for baseline exposure risk to SARS-CoV-2 infection. Green shaded areas show 
the confidence interval around the predicted mean probability (green line). b, d, f, h: Blue shaded areas represent the immune marker density distribution. 
Green lines show the relative risk of infection among vaccine recipients compared to the MenACWY control arm participants. The green lines are the 
median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are 95% bootstrapped confidence intervals for the relative risk.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | Sensitivity analysis showing absolute and relative risk of primary symptomatic SARS-CoV-2 infection in participants with 
symptoms of shortness of breath as a function of immune markers measured at day 28 post-second dose. Results are shown for: a, b: Anti-spike IgG 
measured at 28 days post boost (28 cases, 1155 non-cases included in the analysis). c, d: Anti-RBD IgG measured at 28 days post boost (28 cases, 1155 
non-cases included in the analysis). e, f: Pseudovirus neutralisation antibody titres 28 days post boost (27 cases, 828 non-cases included in the analysis). 
g, h: Live virus neutralisation antibody titres 28 days post boost (22 cases, 412 non-cases included in the analysis). a, c, e, g: Grey horizontal lines show the 
overall risk of primary symptomatic COVID-19 in the control group (MenACWY) and vaccine groups (ChAdOx1 nCoV-19). Blue dots show the absolute 
risk predicted from the model across the range of antibody values included in the analysis, adjusting for baseline exposure risk to SARS-CoV-2 infection. 
Green shaded areas show the confidence interval around the predicted mean probability (green line) b, d, f, h: Blue shaded areas represent the immune 
marker density distribution. Green lines show the relative risk of infection among vaccine recipients compared to the MenACWY control arm participants. 
The green lines are the median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are 95% bootstrapped confidence intervals for 
the relative risk.
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Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | Sensitivity analysis showing absolute and relative risk of primary symptomatic SARS-CoV-2 infection in participants with no 
symptoms of shortness of breath as a function of immune markers measured at day 28 post-second dose. Results are shown for: a, b: Anti-spike IgG 
measured at 28 days post boost (24 cases, 1155 non-cases included in the analysis). c, d: Anti-RBD IgG measured at 28 days post boost (24 cases, 1155 
non-cases included in the analysis). e, f: Pseudovirus neutralisation antibody titres 28 days post boost (20 cases, 828 non-cases included in the analysis). 
g, h: Live virus neutralisation antibody titres 28 days post boost (14 cases, 412 non-cases included in the analysis). a, c, e, g: Grey horizontal lines show the 
overall risk of primary symptomatic COVID-19 in the control group (MenACWY) and vaccine groups (ChAdOx1 nCoV-19). Blue dots show the absolute 
risk predicted from the model across the range of antibody values included in the analysis, adjusting for baseline exposure risk to SARS-CoV-2 infection. 
Green shaded areas show the confidence interval around the predicted mean probability (green line). b, d, f, h: Blue shaded areas represent the immune 
marker density distribution. Green lines show the relative risk of infection among vaccine recipients compared to the MenACWY control arm participants. 
The green lines are the median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are 95% bootstrapped confidence intervals for 
the relative risk.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Sensitivity analysis showing absolute and relative risk primary symptomatic SARS-CoV-2 infection with 3 or more COVID-19 
symptoms as a function of immune markers measured at day 28 post-second dose. Results are shown for: a, b: Anti-spike IgG measured at 28 days 
post boost (32 cases, 1155 non-cases included in the analysis). c, d: Anti-RBD IgG measured at 28 days post boost (32 cases, 1155 non-cases included 
in the analysis). e, f: Pseudovirus neutralisation antibody titres 28 days post boost (28 cases, 828 non-cases included in the analysis). g, h: Live virus 
neutralisation antibody titres 28 days post boost (21 cases, 412 non-cases included in the analysis). a, c, e, g: Grey horizontal lines show the overall risk of 
primary symptomatic COVID-19 in the control group (MenACWY) and vaccine groups (ChAdOx1 nCoV-19). Blue dots show the absolute risk predicted 
from the model across the range of antibody values included in the analysis, adjusting for baseline exposure risk to SARS-CoV-2 infection. Green shaded 
areas show the confidence interval around the predicted mean probability (green line). b, d, f, h: Blue shaded areas represent the immune marker density 
distribution. Green lines show the relative risk of infection among vaccine recipients compared to the MenACWY control arm participants. The green lines 
are the median relative risk obtained from 10,000 bootstrap samples. Green shaded areas are 95% bootstrapped confidence intervals for the relative risk.
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